GENE ONLINE|News &
Market Insight on FDA-approvals: Rise of First-in-class and Regenerative Innovations
Achieving market entry for new drugs has never been more challenging, especially for non-COVID medications during a time shrouded in COVID-19. Notably, the US FDA has pushed to accelerate the launches of non-COVID medications and has been reviewing more next-generation (Next-Gen) drugs in the last 14 months. Next-Gen drugs, here chiefly describing the first-in-class and regeneration ones which encompass strong clinical benefits and market competitions, are evolving fast year on year.
